CVBT Engages Auditors for 2008 through 2011 SEC Reporting

LAS VEGAS, June 28, 2011 /PRNewswire/ -- CardioVascular BioTherapeutics, Inc. (trading symbol: CVBT.PK) today announced it has engaged the Certified Public Accounting Firm, Malone Bailey LLP , to audit the years ending December 31, 2008, 2009 and 2010 and to review the quarterly filings for 2009, 2010, and 2011.

CVBT's CEO, Daniel C. Montano stated, "Our goal is to become compliant with SEC reporting requirements by late Q3 2011. This will allow CVBT to resume our annual shareholder meetings and position the Company to move our stock listing to an exchange."

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing drug candidates for diseases characterized by inadequate blood flow to tissue or organs. The company has three open IND's with the FDA; a Phase III trial to treat chronic diabetic foot ulcers (CVBT-141B) is planned pending FDA approval, a Phase II trial to treat severe coronary heart disease (CVBT-141H), and a Phase I trial to treat peripheral arterial disease (CVBT-141C).

This news release contains forward-looking statements that involve risks and uncertainties. Please see http://www.cvbt.com/terms.shtml for a discussion of forward-looking statements. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.

Media Contact:
Allison Caplan
CardioVascular BioTherapeutics, Inc.
(702) 839-7200
[email protected]

SOURCE CardioVascular BioTherapeutics, Inc.

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

Zydus Cadila has completed a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 .